Path: utzoo!attcan!uunet!crdgw1!uakari.primate.wisc.edu!sdd.hp.com!elroy.jpl.nasa.gov!ucla-cs!Wounded.Bird@f38.n135.z1.fidonet.org
From: Wounded.Bird@f38.n135.z1.fidonet.org (Wounded Bird)
Newsgroups: sci.med.aids
Subject: Re: MILITARY VACCINE TESTING
Message-ID: <39211@shemp.CS.UCLA.EDU>
Date: 22 Sep 90 04:08:41 GMT
Sender: news@CS.UCLA.EDU
Organization: FidoNet node 1:135/38 - C-Board, Miami FL
Lines: 41
Approved: phil@wubios.wustl.edu
Note:	Copyright 1990 by Daniel R. Greening.  Permission granted for
Note:	non-commercial reproduction.
Archive-number: 2500

About a year ago I remember a fellow posting here that he was taking part in 
tests of GP-160. He was saying his employer, The IBM Corporation, had actually 
encouraged people to do so. I remember it so well because some jerk popped in 
with why would you want to risk your life for a bunch of perverts and drug 
abusers? God, I was pissed. <grin> This was a civilian study.

Here is what I have on Gp160. There is an entire chapter on vaccine 
development in the National Academy of Sciences publication "Mobilizing 
Against Aids". ( I know everyone must be getting sick of my reference to that 
book but it's the best source or compendium of data I have run accross):

 "The first human trial of an AIDS vaccine was conducted by Daniel Zagury of 
the Pierre and Marie Curie University in Paris and his coworkers. They 
demonstrated that a vaccinia-gp160 recombinant virus could induce both 
antibody-mediated and cell-mediated immunity against HIV. The vaccine did not 
produce any side effects other than the localized sore associated with a 
satisfactory immune response to vaccinia."

"Phase 1 clinical trials of a gp160 subunit vaccine began at NIAID in the 
summer of 1987. In January 1988 the trial was expanded to include 6 vaccine 
evaluation units at medical centers around the country....A second U.S. 
vaccine, a vaccinia-gp160 recombinant similar to the Zagury vaccine, is being 
tested by researchers associated with the University of Washington."

"These trials will NOT provide any evidence about vaccine efficacy in human 
beings. Clearly, it would be unethical to challenge recipients with live 
virus. The trials are only designed to answer questions about safety and to 
acquire some preliminary information about the effects of the vaccines on the 
immune system."

"Scientists and reporters who cover science have a responsibilty to make it 
very clear that these trials are preliminary safety trials. They do not signal 
the advent of an effective solution to the AIDS problem. Raising false hopes 
could diminish educational efforts that are essential to control the 
epidemic."

AMEN.....W.B.

--  
Uucp: ...{gatech,ames,rutgers}!ncar!asuvax!stjhmc!135!38!Wounded.Bird
Internet: Wounded.Bird@f38.n135.z1.fidonet.org